Oral second-line chemotherapy for advanced non-small-cell lung cancer: The bottom line

被引：7

作者：

Gandara, David R. ^{[1
]}

Davies, Angela M. ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

10.1200/JCO.2006.06.1432

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：2700 / 2701

页数：2

相关论文

共 13 条

[1] XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC):: The STELLAR 2 phase III study [J].

Bonomi, P ;

Paz-Ares, L ;

Langer, C ;

O'Brien, M ;

Gervais, R ;

Gatzemeier, U ;

Reiterer, R ;

Orlov, S ;

Ross, H ;

Vandenbulcke, J .

LUNG CANCER, 2005, 49 :S35-S35

[2] Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial [J].

Dancey, J ;

Shepherd, FA ;

Gralla, RJ ;

Kim, YS .

LUNG CANCER, 2004, 43 (02) :183-194

[3]

Davies AM, 2005, J CLIN ONCOL, V23, p630S

[4] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].

Fossella, FV ;

DeVore, R ;

Kerr, RN ;

Crawford, J ;

Natale, RR ;

Dunphy, F ;

Kalman, L ;

Miller, V ;

Lee, JS ;

Moore, M ;

Gandara, D ;

Karp, D ;

Vokes, E ;

Kris, M ;

Kim, Y ;

Gamza, F ;

Hammershaimb, L .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362

[5] Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? [J].

Gandara, DR ;

Gumerlock, PH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5856-5858

[6] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[7] Economic analysis of the TAX 317 trial: Docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer [J].

Leighl, NB ;

Shepherd, FA ;

Kwong, R ;

Burkes, RL ;

Feld, R ;

Goodwin, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1344-1352

[8]

RAMIAU R, 2005, J CLIN ONCOL S, V23, pS625

[9] Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer [J].

Ramlau, R ;

Gervais, R ;

Krzakowski, M ;

Von Pawel, J ;

Kaukel, E ;

Abratt, RP ;

Dharan, B ;

Grotzinger, KM ;

Ross, G ;

Dane, G ;

Shepherd, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2800-2807

[10]

Sandler AB, 2005, J CLIN ONCOL, V23, p2S